Indeed, four separate anti-PD-1 blocking antibody (ab) clones, nivolumab, pembrolizumab, cemiplimab, and dostarlimab, have been approved by the FDA for the treatment of advanced stage cancers of diverse origin, including the first two for melanoma2. This evidence concerns the gene PDCD1 and cancer.